Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Two Different Doses of Ixazomib Assessed in Patients with Relapsed MM Not Refractory to Bortezomib

Conference Correspondent  - TON - ASH 2015 - Multiple Myeloma, Conference Correspondent

Ixazomib is an oral proteasome inhibitor recently approved by the US Food and Drug Administration for the treatment of relapsed multiple myeloma (MM). In the dose-escalation studies, ixazomib was tolerated up to a dose of 5.5 mg given every week as a single agent, while a dose of 4 mg was utilized in the combination studies with lenalidomide. In this randomized phase 2 study, patients were given ixazomib 4 mg (arm A) or 5.5 mg weekly (arm B) for 3 weeks with a week off along with weekly dexamethasone (40 mg) in patients with relapsed MM. The primary objective was to determine the confirmed overall response rate; secondary objectives included progression-free survival and overall survival. A total of 71 patients were included in the study population; 1 patient was ineligible.

Baseline characteristics were similar in the 2 arms. Participants’ median age was 70 years; 53% were male. The median number of prior therapies was 4 (range, 2-6); 90% of the patients had received prior immunomodulatory drugs, 71% had prior transplant, and 31% had prior bortezomib. At follow-up, 19 (54%) and 22 (63%) patients had disease progression in arms A and B, respectively, and 19 (29%) patients remained on treatment—10 in arm A (29%) and 9 (26%) in arm B. A total of 11 (31%) patients in arm A and 18 (51%) patients in arm B achieved an overall response to treatment. Median event-free survival rates were 8.4 months in arm A and 6.9 months in arm B. Median duration of response was also statistically similar; 16.7 months in arm A and 16.3 months in arm B.

Overall, treatment was well tolerated with 2 patients in arm A and 3 patients in arm B discontinuing treatment for adverse events (AEs). The most common toxicities were fatigue, thrombocytopenia, diarrhea, and nausea, with more grade 3 toxicities among patients in arm B.

Researchers concluded that ixazomib in combination with dexamethasone showed significant antimyeloma activity, relatively deep responses, and primarily manageable toxicities in this group of patients with relapsed MM. The higher dose of ixazomib appears to be associated with a higher response rate as well as a higher rate of AEs requiring dose reductions.

Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017